Autigen siHES1
Sensorineural Hearing Loss (SNHL)
PreclinicalActive
Key Facts
Indication
Sensorineural Hearing Loss (SNHL)
Phase
Preclinical
Status
Active
Company
About Otologic Pharmaceutics
Otologic Pharmaceutics is a pioneering biotech firm targeting the vast, underserved market of sensorineural hearing loss. The company has two core platforms: a Phase II-ready, oral small molecule combination therapy (NHPN-1010) for conditions like tinnitus and acute hearing loss, and a preclinical siRNA-based regenerative program (Autigen siHES1) aimed at regrowing sensory hair cells. While still pre-revenue, the company has secured non-dilutive funding from the Department of Defense and is actively seeking partnerships to advance its pipeline.
View full company profileTherapeutic Areas
Other Sensorineural Hearing Loss (SNHL) Drugs
| Drug | Company | Phase |
|---|---|---|
| Autigen siHES1#7 | Otologic Pharmaceutics | Preclinical |
| Autigen siHES1+GSK3b | Otologic Pharmaceutics | Preclinical |